Valeant Pharmaceuticals was sued by former investors of Sprout Pharmaceuticals over claims the company bungled the marketing of a female libido pill it acquired from Sprout in a $1 billion buyout
of the drugmaker. The lawsuit claims Valeant violated terms by overcharging for Addyi and failed to make promised investments to market the drug.
Read the whole story at Bloomberg »